Elevated expression of histone demethylase PHF8 associates with adverse prognosis in patients of laryngeal and hypopharyngeal squamous cell carcinoma

Epigenomics

Volumn 7, Issue 2, 2015, Pages 143-153

  Zhu, Gangcai ^a,b   Liu, Lijun ^a,c   She, Li ^a,b   Tan, Haolei ^a,b   Wei, Ming ^a,b   Chen, Changhan ^a,b   Su, Zhongwu ^a,b   Huang, Donghai ^a,b   Tian, Yongquan ^a,b   Qiu, Yuanzheng ^a,b   Liu, Yong ^a,b   Zhang, Xin ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Otolaryngology Major Disease Research Key Laboratory of Hunan Province   (China)

^c THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

epigenetic marker; H3K27; H3K9; histone demethylation; laryngeal and hypopharyngeal squamous cell carcinoma; metastasis; PHF8; recurrence; squamous cell carcinoma of the head and neck; survival time

Indexed keywords

HISTONE DEMETHYLASE; PROTEIN PHF8; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; HISTONE; PHF8 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNGEAL AND HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METHYLATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ENZYMOLOGY; HYPOPHARYNX TUMOR; LARYNX TUMOR; METABOLISM; MORTALITY; PROGNOSIS; SURVIVAL; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; HISTONE DEMETHYLASES; HISTONES; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; MALE; METHYLATION; PROGNOSIS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS;

EID: 84928885388     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.82     Document Type: Article

References (45)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 64(1), 9-29 (2014).
2. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer 97(1), 72-81 (2002).
3. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 371(9625), 1695-1709 (2008).
4. Sturgis EM. The International Head and Neck Cancer Epidemiology Consortium. Head Neck 33(1), 141 (2011).
5. Elsheikh MN, Rinaldo A, Hamakawa H et al. Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma. Head Neck 28(9), 842-849 (2006).
6. Russo N, Wang X, Liu M et al. A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature. Oncogene 32(42), 5026-5037 (2013).
7. Rozov SM, Berdnikov VA, Gorel FL, Lavrenteva MV, Solonenko LP. [Structural characteristics of lysine-rich histone from the sperm of a mollusk Anodonta piscinalis]. Mol. Biol. (Mosk.) 18(6), 1497-1508 (1984).
8. Cheng CS, Rai K, Garber M et al. Semiconductor-based DNA sequencing of histone modification states. Nat. Commun. 4, 2672 (2013).
9. Fischle W. Molecular mechanisms of histone modification function. Biochim. Biophys. Acta 1839(8), 621-622 (2014).
10. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 15(18), 2343-2360 (2001).
11. Bannister AJ, Kouzarides T. Reversing histone methylation. Nature 436(7054), 1103-1106 (2005).
12. Carr SM, Munro S, Zalmas LP et al. Lysine methylationdependent binding of 53BP1 to the pRb tumor suppressor. Proc. Natl Acad. Sci. USA 111(31), 11341-11346 (2014).
13. Barski A, Cuddapah S, Cui KR et al. High-resolution profiling of histone methylations in the human genome. Cell 129(4), 823-837 (2007).
14. Bannister AJ, Zegerman P, Partridge JF et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410(6824), 120-124 (2001).
15. Lachner M, OCarroll N, Rea S, Mechtler K, Jenuwein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410(6824), 116-120 (2001).
16. Czermin B, Melfi R, Mccabe D, Seitz V, Imhof A, Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites. Cell 111(2), 185-196 (2002).
17. Yamane K, Tateishi K, Klose RJ et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol. Cell 25(6), 801-812
18. Liu G, Bollig-Fischer A, Kreike B et al. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 28(50), 4491-4500 (2009).
19. Biron VL, Mohamed A, Hendzel MJ, Underhill DA, Seikaly H. Epigenetic differences between human papillomaviruspositive and -negative oropharyngeal squamous cell carcinomas. J. Otolaryngol. Head N. 41, S65-S70 (2012).
20. Gannon OM, De Long LM, Endo-Munoz L, Hazar- Rethinam M, Saunders NA. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation. Clin. Cancer Res. 19(2), 428-441 (2013).
21. Bragado P, Estrada Y, Sosa MS et al. Analysis of markerdefined HNSCC subpopulations reveals a dynamic regulation of tumor initiating properties. PLoS ONE 7(1), e29974 (2012).
22. Laytragoon-Lewin N, Castro J, Elmberger G et al. DNA methylation in tumour and normal mucosal tissue of head and neck squamous cell carcinoma (HNSCC) patients - new diagnostic approaches and treatment. Eur. J. Cancer 47, S545-S545 (2011).
23. Feng WJ, Yonezawa M, Ye J, Jenuwein T, Grummt I. PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1/2 demethylation. Nat. Struct. Mol. Biol. 17(4), 445-450 (2010).
24. Yu L, Wang Y, Huang S et al. Structural insights into a novel histone demethylase PHF8. Cell Res. 20(2), 166-173 (2010).
25. Qi HH, Sarkissian M, Hu GQ et al. Histone H4K20/H3K9 demethylase PHF8 regulates zebrafish brain and craniofacial development. Nature 466(7305), 503-507 (2010).
26. Pasini D, Hansen KH, Christensen J, Agger K, Cloos PaC, Helin K. Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and polycomb-repressive complex 2. Genes Dev. 22(10), 1345-1355 (2008).
27. Shen YZ, Pan XF, Zhao H. The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer. Biochem. Biophys. Res. Commun. 451(1), 119-125 (2014).
28. Bjorkman M, Ostling P, Harma V et al. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. Oncogene 31(29), 3444-3456 (2012).
29. Sun XJ, Qiu JJ, Zhu ST et al. Oncogenic features of PHF8 histone demethylase in esophageal squamous cell carcinoma. PLoS ONE 8(10), e77353 (2013).
30. Lim HJ, Dimova NV, Tan MK, Sigoillot FD, King RW, Shi Y. The G2/M regulator histone demethylase PHF8 is targeted for degradation by the anaphase-promoting complex containing CDC20. Mol. Cell. Biol. 33(21), 4166-4180 (2013).
31. Wang J, Lin XQ, Wang S et al. PHF8 and REST/NRSF cooccupy gene promoters to regulate proximal gene expression. Sci. Rep. 4, 5008 (2014).
32. Asensio-Juan E, Gallego C, Martinez-Balbas MA. The histone demethylase PHF8 is essential for cytoskeleton dynamics. Nucleic Acids Res. 40(19), 9429-9440 (2012).
33. Liu Y, Xie CL, Zhang X et al. Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur. J. Cancer 46(16), 3007-3015 (2010).
34. Zhu G, Cai G, Liu Y et al. Quantitative iTRAQ LC-MS/ MS proteomics reveals transcription factor crosstalk and regulatory networks in hypopharyngeal squamous cell carcinoma. J. Cancer 5(7), 525-536 (2014).
35. Filleron T, Laplanche A, Boher JM, Kramar A. An R function to non-parametric and piecewise analysis of competing risks survival data. Comput. Methods Programs Biomed. 100(1), 24-38 (2010).
36. R Foundation for Statistical Computing. R: a language and environment for statistical computing. www.R-project.org
37. Liu W, Tanasa B, Tyurina OV et al. PHF8 mediates histone H4 lysine 20 demethylation events involved in cell cycle progression. Nature 466(7305), 508-512 (2010).
38. Yatim A, Benne C, Sobhian B et al. NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function. Mol. Cell 48(3), 445-458 (2012).
39. Fortschegger K, De Graaf P, Outchkourov NS, Van Schaik FM, Timmers HT, Shiekhattar R. PHF8 targets histone methylation and RNA polymerase II to activate transcription. Mol. Cell. Biol. 30(13), 3286-3298 (2010).
40. Wysocka J, Swigut T, Xiao H et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442(7098), 86-90 (2006).
41. Wend P, Fang L, Zhu Q et al. Wnt/beta-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours. EMBO J. 32(14), 1977-1989 (2013).
42. Sundar IK, Yao H, Rahman I. Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases. Antioxid. Redox Signal. 18(15), 1956-1971 (2013).
43. Johann DJ Jr, Mcguigan MD, Patel AR et al. Clinical proteomics and biomarker discovery. Ann. NY Acad. Sci. 1022, 295-305 (2004).
44. Masood R, Hochstim C, Cervenka B et al. A novel orthotopic mouse model of head and neck cancer and lymph node metastasis. Oncogenesis 2, e68 (2013).
45. Hojfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat. Rev. Drug Discov. 12(12), 917-930 (2013).